1067239-08-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-3-carboxylic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to be further modified and incorporated into various drug molecules. The presence of the Boc group allows for selective protection of amines during multi-step synthesis processes, while the hydroxyl and carboxylic acid groups provide functional groups for further chemical reactions.
Used in Agrochemical Industry:
1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-3-carboxylic acid is used as an intermediate in the synthesis of agrochemicals, such as pesticides and herbicides, due to its potential to be modified and incorporated into various agrochemical molecules. The versatility of the compound's functional groups allows for the development of new and effective agrochemicals with improved properties.
Used in Organic Synthesis:
1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-3-carboxylic acid is used as a building block in organic synthesis for its ability to be further modified and used in the creation of a wide range of organic compounds. The Boc group, hydroxyl group, and carboxylic acid group provide opportunities for various chemical reactions, making it a valuable compound in the synthesis of complex organic molecules.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 75315-60-5 3-hydroxypyrrolidine-3-carboxylic acid 
• 7677-24-9 trimethylsilyl cyanide 
• 101385-93-7 3-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Preparation method of oxazaspiro compound

The invention discloses a preparation method of an oxazaspiro compound, which comprises the following steps: by using substituted saturated azaspiro alkane (compound II) as a raw material, performinghydrolyzing under an alkaline condition to obtain a compound III; carrying out condensation reaction on the compound III and a salt of a compound IV (halogenated alkylamine)/compound IV to generate acompound V; and finally, cyclizing the compound V under an alkaline condition to obtain the lactam oxazaspiro compound I.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS

A method for treating a urinary tract infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Ql, Q2, Rl, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds of structure (I): having antibacterial activity are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.